ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

B. Eichhorst; P. Ghia; C. U. Niemann; A. P. Kater; M. Gregor; M. Hallek; M. Jerkeman; ESMO Guidelines Committee

doi:10.1016/j.annonc.2024.06.016

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

B. Eichhorst
, P. Ghia
, C. U. Niemann
, A. P. Kater
, M. Gregor
, M. Hallek
, M. Jerkeman
, ESMO Guidelines Committee

University of Cologne
Vita-Salute San Raffaele University
Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
University of Copenhagen
Kantonsspital Luzern
Lund University
Ulm University

Research output: Contribution to journal › Article › Academic › peer-review

141 Downloads (Pure)

Original language	English
Pages (from-to)	762-768
Number of pages	7
Journal	Annals of oncology
Volume	35
Issue number	9
Early online date	2024
DOIs	https://doi.org/10.1016/j.annonc.2024.06.016
Publication status	Published - Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BCL2 inhibitor
BTK inhibitor
chronic lymphocytic leukaemia
guideline update
ibrutinib–venetoclax
time-limited targeted therapy

Access to Document

10.1016/j.annonc.2024.06.016

Esmo-clinical-practice-guideline-interim-update-on-new-targeted-therapies-in-the-first-line-and-at-relapse-of-chronic-ly.pdfFinal published version, 569 KBLicence: Taverne

Cite this

@article{8ae31b9b7e0c47f8885d695523847a50,

title = "ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia",

keywords = "BCL2 inhibitor, BTK inhibitor, chronic lymphocytic leukaemia, guideline update, ibrutinib–venetoclax, time-limited targeted therapy",

author = "B. Eichhorst and P. Ghia and Niemann, \{C. U.\} and Kater, \{A. P.\} and M. Gregor and M. Hallek and M. Jerkeman and \{ESMO Guidelines Committee\} and C. Buske",

year = "2024",

month = sep,

doi = "10.1016/j.annonc.2024.06.016",

language = "English",

volume = "35",

pages = "762--768",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

AU - Eichhorst, B.

AU - Ghia, P.

AU - Niemann, C. U.

AU - Kater, A. P.

AU - Gregor, M.

AU - Hallek, M.

AU - Jerkeman, M.

AU - ESMO Guidelines Committee

AU - Buske, C.

PY - 2024/9

Y1 - 2024/9

KW - BCL2 inhibitor

KW - BTK inhibitor

KW - chronic lymphocytic leukaemia

KW - guideline update

KW - ibrutinib–venetoclax

KW - time-limited targeted therapy

UR - https://www.scopus.com/pages/publications/85199699993

U2 - 10.1016/j.annonc.2024.06.016

DO - 10.1016/j.annonc.2024.06.016

M3 - Article

C2 - 38969011

SN - 0923-7534

VL - 35

SP - 762

EP - 768

JO - Annals of oncology

JF - Annals of oncology

IS - 9

ER -

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

UN SDGs

Keywords

Access to Document

Other files and links

Cite this